Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Ablynx nv
Ablynx nv
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Media
Sanofi completes acquisition of Ablynx
Sanofi has now acquired all outstanding shares, warrants and convertible bonds of Ablynx following the expiration of the Squeeze-out procedure
Research & Development
Sanofi to acquire Ablynx for €3.9 billion
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules
Recruitment
Ablynx appoints Dr Robert Friesen as Chief Scientific Officer
Research & Development
Ablynx announces board changes
Finance
Ablynx appoints General Manager
Pharmaceutical
Ablynx appoints Markus Ewert as CBO
Research & Development
Novel Nanobody to begin clinical development in osteoarthritis
Ablynx to receive €15m milestone payment from Merck
Subscribe now